

**Amendments to the Claims:**

**This listing of claims will replace all prior versions and listings of claims in the application.**

1 to 15. (Canceled)

16. (Previously Presented) A method for inhibiting fusion between a membrane of a paramyxovirus and a plasma membrane of a cell comprising administering to a subject in need thereof a composition comprising an effective amount of at least one polypeptide sequence of SEQ ID NO: 1 or SEQ ID NO: 2 and a pharmaceutically acceptable carrier.

17. (Previously Presented) The method of claim 16, wherein said paramyxovirus is of the genus *Henipavirus*.

18. (Currently Amended) The method of claim 16, wherein said paramyxovirus is of the subfamily *Paramyxovirinae* ~~*Paramyxovirina*~~.

19. (Currently Amended) The method of claim 16, wherein said virus is Hendra virus (HeV) or Nipah virus (NiV) ~~HeV or NiV~~.

20 to 22. (Canceled)

23. (Currently Amended) A method for inducing an immune response to ~~treating infection with~~ a virus, comprising administering to a subject in need thereof a composition comprising an effective amount of at least one polypeptide sequence of SEQ ID NO: 1 or SEQ ID NO: 2 and a pharmaceutically acceptable carrier.

24. (Previously Presented) The method of claim 23, wherein said virus is a paramyxovirus.

25. (Previously Presented) The method of claim 23, wherein said paramyxovirus is of the genus *Henipavirus*.

26. (Currently Amended) The method of claim 23, wherein said virus is Hendra virus (HeV) or Nipah virus (NiV) ~~HeV or NiV~~.

27 to 30. (Canceled)

31. (Currently Amended) A method of inducing an immune response to ~~for treating or preventing infection~~ by a paramyxovirus, comprising administering to a subject in need thereof a pharmaceutically effective amount of a composition comprising at least one polypeptide selected from the group consisting of:
- (a) a polypeptide comprising SEQ ID NO: 1; and
  - (b) a polypeptide comprising SEQ ID NO: 2.
32. (Previously Presented) The method of claim 31, wherein the method comprises administering a polypeptide comprising SEQ ID NO: 1.
33. (Previously Presented) The method of claim 31, wherein the method comprises administering a polypeptide comprising SEQ ID NO: 2.
34. (Previously Presented) The method of claim 31, wherein the method comprises administering a polypeptide consisting of SEQ ID NO: 1.
35. (Previously Presented) The method of claim 31, wherein the method comprises administering a polypeptide consisting of SEQ ID NO: 2.
36. (Previously Presented) The method of claim 31, wherein the subject is human.
37. (Previously Presented) The method of claim 31, wherein the composition further comprises a pharmaceutically acceptable carrier.
38. (Previously Presented) The method of claim 37, wherein the composition is formulated for oral administration, subcutaneous injection, intravenous injection, intramuscular injection, or intraperitoneal injection.
39. (Previously Presented) The method of claim 31, wherein the composition is formulated as a vaccine.
40. (Previously Presented) The method of claim 31, wherein said paramyxovirus is of the genus *Henipavirus*.
41. (Currently Amended) The method of claim 31, wherein said paramyxovirus is of the subfamily *Paramyxovirinae* ~~*Paramyxovirina*~~.

42. (Currently Amended) The method of claim 31, wherein said virus is Hendra virus (HeV) or Nipah virus (NiV) ~~HeV or NiV~~.
43. (Previously Presented) The method of claim 31, wherein the polypeptide comprises at least one second polypeptide.
44. (Currently Amended) The method of claim 31, wherein the polypeptide is a fusion protein comprising a polypeptide comprising SEQ ID NO: 1 or SEQ ID NO: 2.
45. (Previously Presented) The method of claim 31, wherein the method comprises administering a composition comprising a polypeptide comprising SEQ ID NO: 1 and a polypeptide comprising SEQ ID NO: 2.
46. (Previously Presented) The method of claim 31, wherein the polypeptide comprises SEQ ID NO: 1 and SEQ ID NO: 2.